Scleroderma lung disease: "if you don't know where you are going, any road will take you there".

" If you don't know where you are going, any road will take you there. " It is one of my favorite sayings. It always reminds me that if you and I don't have a plan of some kind, then we will wander aimlessly toward whatever. And generally, if we have not thought out where we are going, or where we would like to go, then other people, or life circumstances, will create the way for us. I heard this catchy saying maybe twenty-five years ago and have thought about it many times. Although I did not hear it from this source, everyone seems to think it comes from a scene in Alice in Wonderland in an exchange between Alice and the Cat. Said Alice: " Would you tell me, please, which way I ought to go from here? " Said the Cat: " That depends a good deal on where you want to get to. " " I don't much care where – " said Alice. " Then it doesn't matter which way you go, " said the Cat. " – so long as I get SOMEWHERE, " Alice added as an explanation. " Oh, you're sure to do that, " said the Cat, " if you only walk long enough. " Back in the '90s, Stephen Covey taught us his Seven Habits of Highly Effective People. One of his principles is, " Beginning with the end in mind. " I'll edit and paraphrase what he says:

[1]  A. Nicholson,et al.  Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. , 2003, American journal of respiratory and critical care medicine.

[2]  Charlie Strange,et al.  Cyclophosphamide versus placebo in scleroderma lung disease. , 2006, The New England journal of medicine.

[3]  F. Martinez,et al.  Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. , 2006, American journal of respiratory and critical care medicine.

[4]  C. Vogelmeier,et al.  Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. , 1996, American journal of respiratory and critical care medicine.

[5]  R. Elashoff,et al.  Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. , 2007, American journal of respiratory and critical care medicine.

[6]  A. Wells,et al.  Daily cyclophosphamide for scleroderma: are patients with the most to gain underrepresented in this trial? , 2007, American journal of respiratory and critical care medicine.

[7]  D. Hansell,et al.  Interstitial lung disease in systemic sclerosis: a simple staging system. , 2008, American journal of respiratory and critical care medicine.

[8]  J. Tooze,et al.  Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. , 2001, American journal of respiratory and critical care medicine.

[9]  F. Martinez,et al.  Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. , 2003, American journal of respiratory and critical care medicine.

[10]  R. Wise,et al.  Cyclophosphamide Is Associated with Pulmonary Function and Survival Benefit in Patients with Scleroderma and Alveolitis , 2000, Annals of Internal Medicine.

[11]  P. Emery,et al.  A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. , 2006, Arthritis and rheumatism.

[12]  R. Elashoff,et al.  Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. , 2008, American journal of respiratory and critical care medicine.

[13]  T. Medsger,et al.  Changes in causes of death in systemic sclerosis, 1972–2002 , 2007, Annals of the rheumatic diseases.